ARVEN - Trademark Details
Status: 700 - Registered
Image for trademark with serial number 79164550
Serial Number
79164550
Registration Number
5061369
Word Mark
ARVEN
Status
700 - Registered
Status Date
2016-10-18
Filing Date
2014-10-01
Registration Number
5061369
Registration Date
2016-10-18
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2016-08-02
Attorney Name
Law Office Assigned Location Code
M90
Employee Name
YAO, GRETTA
Statements
Goods and Services
Pharmaceuticals and pharmaceutical preparations for the prevention and treatment of cardiovascular disorders, skeleto-muscular disorders, general infections, viral infections, central nervous system disorders, gastro-intestinal disorders, fungal diseases, allergy, ophthalmic diseases, hemophilia, metabolic diseases, cancer, multiple sclerosis, neutropenia, non-Hodgkin lymphoma, Crohn's Disease, autoimmune disorders, urologic diseases, sexual dysfunction, osteoporosis, and climacteric diseases; pharmaceutical preparations, namely, anticoagulants and platelet aggregation inhibitors, contraceptive preparations, analgesics, anti-pyretics, anti-inflammatory preparations, anti-septic preparations, medicated lip balm, anesthetic spray for topical use, astringents, pediculicides, decongestants, antifungal agents, anti-infective pharmaceutical preparations, antacids, cold preparations in the nature of preparations for treating colds, menstrual symptom treatment preparations and dermatologicals; Pharmaceuticals and pharmaceutical preparations, namely, dry powder inhalers filled with pharmaceutical preparations for the treatment of asthma and respiratory diseases; Inhalation products, namely, inhalers filled with pharmaceutical preparations for the treatment of asthma, respiratory diseases; pharmaceutical preparations used in medical diagnostic procedures, namely, contrast media for use with x-ray, magnetic resonance and ultrasound equipment; veterinary preparations for medical use, namely, anesthetics, combination sedative, analgesic; veterinary preparations for medical use for the treatment of bacterial infections; pharmaceutical preparations, namely, Systemic anti-infectives, namely, antibacterial and antifungal pharmaceuticals; mineral preparations, namely, vitamin and mineral supplements, vitamin and mineral preparations for medical use, vitamin preparations and mineral supplements; Musculo-skeletal system pharmaceutical products for the treatment of musculo-skeletal system diseases; Cardiovascular pharmaceuticals, namely, diuretics, lipid lowering agents, beta blocking agents, calcium antagonists and cardiovascular treatment preparations and cardiovascular agents for medical purposes; Pharmaceuticals for the prevention and treatment of disorders of the nervous system, namely, analgesics, psychoanaleptics, psycoleptics, anti-epileptics, central nervous system drugs, anaesthetics, antiparkinson preparations; Pharmaceuticals for the treatment of respiratory diseases and asthma; Dermatological pharmaceutical products; Pharmaceuticals for the treatment of hormonal disorders and the prevention of osteoporosis; Anti-diabetic pharmaceuticals; Pharmaceuticals for the treatment of bone diseases and joint diseases; Pharmaceuticals for the treatment of viral and infectious diseases; Pharmaceuticals for use as antineoplastic agents; Pharmaceuticals for the treatment of immune system related diseases and disorders; Pharmaceuticals for the treatment of kidney diseases; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals for ophthalmological use; pharmaceutical preparations for the treatment of cardiovascular disorders, skeleto-muscular disorders, general infections, viral infections, central nervous system disorders, gastro-intestinal disorders, fungal diseases, erectile dysfunction, respiratory diseases, allergy, ophthalmic diseases, containing one or more of the following active ingredients - cromolin sodium, amlodipin besylate, alendronate sodium, chlorazepate dipotassium, atropine sulphate, atorvastatin calcium, candesartan cilexetil, ceftriaxone sodium, ephedrine hcl, guaiphenesine, zafirlukast, donepezil hcl, diflunisal, dipyridamole, famotidine, losartan potassium, hydro-chlorothiazide, meloxicam, phenyleprine hcl, fexofenadine hcl, indapamide, sulfisoxazole, clopidogrel, lansoprazole, clarithromycin, flurbiprofen, nimesulide, pantoprazole, paracetamole, pilocarpine hcl, lisinopril, pseudoephedrine hcl, ciprofloxacin hcl, sertraline hcl, cyclopentolate hcl, dihydroergotoxine methansulfonate, terbinafine, timolol maleate, tiamphenicol, azithromycin, tenoxicam, fluconazole, digoxine, tioconazole, dimenhydrinate, quinidine arabogalactane sulphate, quinidine phenylethyl barbiturate, diltiazem hcl, buspirone hcl, amiodarone hcl, trazodone, difluprednate, enoxacin, lactulose, ketorolac, pentoxifylline, vitamin e, chlorhexidine, cetrimide, propyphenazone, caffeine, cetirizine, phenylpropanolamine, zolpidem, bacampicillin hcl, roxithromycin, sultamicillin tosilate, acetylsalicylic acid, ampicillin na, sulbactam na, sildenafil citrate, ambroxol hcl, ribavirin, loratadine, etodolac, omeprazole, oxybutynin chloride, quinidine sulphate, olanzapine, raloxifen, pioglitazone, moxifloxacin, rosiglitazone, sibutramin, carvedilol, montelukast, citalopram, gliclazide, cefaclor, ezetimibe, rofecoxib, quetiapine fumarate, metformin hcl, acarbose, chlorpheniramine maleate, nateglinide, leflunomide, valsartan, cefazolin sodium, diacerein, paroxetine, levofloxacin, levetiracetam, zolmitriptan, glibenclamide, tizanidine, perindopril erbumine, ramipril, ceftazidime, cefuroxime axetyl, thiocolchicoside, acamprosate, acetylcysteine, alpha calcidol, alpha lipoic acid, aripiprazole, atomoxetine, balsalazide disodium, butenafine hcl, calcitriol, carbonyl iron, folic acid, calcium carbonate, magnesium hydroxide, cefdinir, cefepime hcl, cefixime, cefpodoxime proxetil, cefprozil, cephalexine monohydrate, ciclesonide, cilazapril, cilostazol, cinitapride, citicoline, co-enzyme q10, darifenasin, deferiprone, dothiepin, duloxetine, eletriptan, escitalopram, esomeprazole, etoricoxib, felodipine, fenofibrate, ferrous sulphate, zinc sulphate, fluvastatin, frovatriptan, gabapentin, galantamine, gemifloxacin, ginkgo biloba, glimepride, granisetron, ibandronate, irbesartan, iron hydroxide polymaltose, lamivudine, lamotrigine, levetiracetam, letrozole, linezolide, memantine hcl, metoprolol, midodrine, mirtazapine, mizolastine, mosapride citrate dihydrate, mycophenolate mofetil, nebivolol, nefazodone, niacin, nitazoxanide, ondansetron, ornidazole, oxcarbazepine, pimecrolimus, pravastatin, pregabalin, rabeprazol, rebamipide, repaglinide, risedronate, risperidone, rivastigmine, rosuvastatin, saccharomyces boulardii, tacrolimus, tadalafil, tamsulosin hcl, tazaroten, tazobactam sodium, piperacillin sodium, tegaserod, telithromycin, terazocin, teriparatide, tolterodine tartrate, topiramate, trandolapril, trimethazidine, valacyclovir, valproate sodium, venlafaxine, voriconazole, ximelagatran, zaleplon, ziprasidone, zoledronic acid
Translation of Words in Mark
The wording "ARVEN" has no meaning in a foreign language.
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2015-05-11
Primary Code
005
Current Trademark Owners
Party Type
30 - Original Registrant
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Type
30 - Original Registrant
Address
Please log in with your Justia account to see this address.
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Party Type
10 - Original Applicant
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Aylin Demirci
Address
Please log in with your Justia account to see this address.
International Registrations
International Registration Number
1245424
International Registration Date
2014-10-01
International Publication Date
2015-05-07
International Renewal Date
2024-10-01
Auto Protection Date
2016-11-07
International Status
001 - Request for extension of protection established
International Status Date
2015-05-07
Priority Claimed In
False
First Refusal In
True
Trademark Events
Event DateEvent Description
2015-05-07SN ASSIGNED FOR SECT 66A APPL FROM IB
2015-05-11NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2015-05-11ASSIGNED TO EXAMINER
2015-05-12NON-FINAL ACTION WRITTEN
2015-05-13NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
2015-05-13REFUSAL PROCESSED BY MPU
2015-05-13NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
2015-05-15APPLICATION FILING RECEIPT MAILED
2015-06-01TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
2015-06-01ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
2015-06-02REFUSAL PROCESSED BY IB
2015-11-12TEAS RESPONSE TO OFFICE ACTION RECEIVED
2015-11-30ASSIGNED TO LIE
2015-12-10ASSIGNED TO LIE
2015-12-15CORRESPONDENCE RECEIVED IN LAW OFFICE
2015-12-15TEAS/EMAIL CORRESPONDENCE ENTERED
2016-01-05FINAL REFUSAL WRITTEN
2016-01-05FINAL REFUSAL E-MAILED
2016-01-05NOTIFICATION OF FINAL REFUSAL EMAILED
2016-06-23EXAMINERS AMENDMENT -WRITTEN
2016-06-23EXAMINERS AMENDMENT E-MAILED
2016-06-23NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
2016-06-23EXAMINER'S AMENDMENT ENTERED
2016-06-23APPROVED FOR PUB - PRINCIPAL REGISTER
2016-06-29LAW OFFICE PUBLICATION REVIEW COMPLETED
2016-07-13NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2016-07-13NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
2016-07-13NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
2016-08-02PUBLISHED FOR OPPOSITION
2016-08-02OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2016-08-12NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
2016-10-12NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
2016-10-12NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
2016-10-18REGISTERED-PRINCIPAL REGISTER
2016-11-18NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
2017-01-18FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
2017-02-23GENERIC MADRID TRANSACTION CREATED
2017-02-23GENERIC MADRID TRANSACTION SENT TO IB
2017-07-14FINAL DECISION TRANSACTION PROCESSED BY IB
2018-01-25NEW REPRESENTATIVE AT IB RECEIVED
2020-05-07NEW REPRESENTATIVE AT IB RECEIVED
2021-10-18COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED